pharmaphorum

FEBRUARY 28, 2022

UK Health Secretary Sajid Javid has said he wants to accelerate the rollout of electronic patient records (EPR) in the NHS, with 90% of NHS trusts using them by the end of 2023. Javid laid out the new target in a speech to the HSJ Digital Transformation Summit, in which he said that current estimates are that one in five NHS trusts still do not have EPR, and so are missing out on a key technology to deliver better, safer care for patients.

Documentation 112

Documentation Communication 112

Outsourcing Pharma

FEBRUARY 28, 2022

The recent Outsourcing-Pharma webinar hosted a trio of industry experts highlighting challenges, opportunities, and innovations in the rare disease realm.

98

98

pharmaphorum

FEBRUARY 28, 2022

A new study has suggested that the economic burden posed by rare diseases is around 10 times higher than for common “mass market” conditions. The analysis by IQVIA and pharma company Chiesi looked at the per patient, per year (PPPY) direct, indirect and mortality-related costs associated with 24 rare diseases, and compared them to 24 chronic ailments like diabetes, heart disease, arthritis and cancers.

Documentation 98

Documentation Hospitals 98

Outsourcing Pharma

FEBRUARY 28, 2022

With a specific focus on clinical trials involving treatments for rare diseases, Orphan Reach seeks to build upon the services that conventional CROs offer.

94

94

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

FEBRUARY 28, 2022

Amryt Pharma has been handed a major blow by the FDA, after the US regulator rejected its marketing application for Oleogel-S10, its drug for rare and debilitating skin disease epidermolysis bullosa (EB). Shares in the Ireland-based rare disease specialist fell sharply after news of the complete response letter (CRL) from the FDA emerged, with the agency asking for “additional confirmatory evidence of effectiveness” for cutaneous manifestations of dystrophic and junctional EB.

FDA 98

FDA 98

Fuld

FEBRUARY 28, 2022

Competitive Intelligence [CI] has gone through an evolution since becoming a corporate function nearly 4 decades ago. Once viewed as a niche area handled by somebody with the background of a CIA operative, we have seen tremendous growth in businesses adopting and implementing best practices to change how work is done and how intelligence is applied to business issues.

52

52

Roots Analysis

FEBRUARY 28, 2022

Over the past few years, the pharmaceutical industry is growing a tremendous pace. Considering patient’s health and safety, the drug products are expected to be free from microbial contamination and should be safe for use throughout the drug’s life cycle. Therefore, several quality checks are performed to ensure product’s sterility and stability. One of the stages that require quality assurance is packaging of the drug product, as compromised packaging could have serious consequences.

Packaging 52

Packaging Immunization 52

pharmaphorum

FEBRUARY 28, 2022

India’s Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its position on the international stage. . Biocon is paying $2.3 billion in cash and providing another $1 billion in stock under the terms of the deal, which has been approved by the boards of both companies and is expected to close in the second half of this year.

Customer Service 93

Customer Service 93

Outsourcing Pharma

FEBRUARY 28, 2022

Ergomed, a global contract research organization, is partnering with Trialbee to improve patient recruitment at its new Rare Disease Innovation Center.

52

52

pharmaphorum

FEBRUARY 28, 2022

It looks like GlaxoSmithKline’s concerns about its respiratory syncytial virus (RSV) vaccine in pregnant women aren’t going to be resolved quickly. After suspending three trials of the much-anticipated vaccine earlier this month to investigate a safety signal, the pharma group has now gone a step further, stopping all enrolment and vaccination in the studies.

Vaccines 72

Vaccines Hospitals 72

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

FEBRUARY 28, 2022

Unmet need among over 7000 rare diseases is being addressed in a comprehensive action plan

49

49

pharmaphorum

FEBRUARY 28, 2022

Johnson & Johnson and the ‘big three’ US pharm wholesalers say they are close to finalising a $26 billion settlement that could allow them to finally put years of litigation over their role in fuelling the opioid crisis behind them. The settlement is the largest to date among thousands of opioid-related lawsuits brought against pharma companies and distributors.

59

59

Pharma Times

FEBRUARY 28, 2022

Quviviq can be used on a long-term basis, addressing a key limitation of existing therapies

46

46

pharmaphorum

FEBRUARY 28, 2022

Alphabet’s Verily Life Science has contracted UK biotech Oncimmune to investigate autoantibodies in people who have developed long-lasting symptoms after COVID-19 infection, a condition known as ‘long COVID’ The aim of the project is to try to find patterns of autoantibodies – antibodies that react with self antigens – that are present early on in COVID-19 infection that are associated with the development of long COVID , also known as post-acute sequelae SARS-CoV-2 (PASC) infe

Immunization 52

Immunization Hospitals 52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

FEBRUARY 28, 2022

SMi is delighted to announce the 6th annual Pre-Filled Syringes West Coast conference, to be held in San Diego. As part of SMi’s leading series of drug delivery device conferences, the 2022 event will provide insights into the rapidly accelerating market of combination product development with industry, device developer and regulatory perspectives. The last year has seen major advances in device design and development with patient usability, ease of use and safety remaining at the forefront.

Packaging 52

Packaging Vaccines 52